Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
National Institutes of Health Clinical Center (CC)
Novelwise Pharmaceutical Corporation
Tango Therapeutics, Inc.
NaviFUS Corporation
Hoosier Cancer Research Network
Stemline Therapeutics, Inc.
Weill Medical College of Cornell University
Stanford University
National Institutes of Health Clinical Center (CC)
Baptist Health South Florida
Neonc Technologies, Inc.
Stanford University
H. Lee Moffitt Cancer Center and Research Institute
Ohio State University Comprehensive Cancer Center
Hoosier Cancer Research Network
University of Utah
Wayshine Biopharm, Inc.
Cedars-Sinai Medical Center
Eikon Therapeutics
Case Comprehensive Cancer Center
Hunan Cancer Hospital
Northwell Health
Northwell Health
Plus Therapeutics
Essen Biotech
Fudan University